Opinion statement
Neuromyelitis optica (Devic’s syndrome) is an uncommon, idiopathic, demyelinating syndrome of the central nervous system that preferentially affects the optic nerves and spinal cord. It frequently is misdiagnosed as severe multiple sclerosis, but usually is readily distinguished from multiple sclerosis in fully developed cases because of its severity, typical magnetic resonance imaging (MRI) findings (normal brain MRI; longitudinally extensive lesions on spinal cord MRI), and cerebrospinal fluid analysis (polymorphonuclear pleocytosis and absence of oligoclonal banding). A serum auto-antibody marker, NMO-IgG, is highly specific for the disorder. Most patients have relapsing disease, and natural history studies confirm early and severe disability. We treat acute myelitis and optic neuritis exacerbations with parenteral corticosteroids and use rescue plasmapheresis for severe, refractory attacks. Immunomodulatory drugs used for typical multiple sclerosis seem ineffective for relapse prevention. We recommend systemic immunosuppression, usually with azathioprine and oral cortico-steroids, for most patients. Fulminant disease and breakthrough disease may respond to other forms of humoral immunotherapy such as rituximab.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinsh-enker BG: The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999, 53:1107–1114. This is the largest contemporary longitudinal series of patients with NMO.
Cree BA, Goodin DS, Hauser SL: Neuromyelitis optica. Semin Neurol 2002, 22:105–122.
Mandler RN, Davis LE, Jeffery DR, Kornfeld M: Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993, 34:162–168.
O’Riordan JI, Gallagher HL, Thompson AJ, et al.: Clinical, CSF, and MRI findings in Devic’s neuro-myelitis optica. J Neurol Neurosurg Psychiatry 1996, 60:382–387.
Weinshenker BG: Neuromyelitis optica: what it is and what it might be. Lancet 2003, 361:889–890.
Wingerchuk DM: Neuromyelitis optica: current concepts. Front Biosci 2004, 9:834–840.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinc-tion from multiple sclerosis. Lancet 2004, 364:2106–2112. The first report of a serum biomarker, NMO-IgG, for CNS demyelinating diseases. The marker seems highly specific for NMO and suggests that NMO and the Japanese opticospinal form of MS are the same disorder.
Kira J: Multiple sclerosis in the Japanese population. Lancet Neurology 2003, 2:117–127. This is an excellent review.
Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002, 125:1450–1461. This modern, detailed immunopathologic study has added substantial weight to the argument that NMO is a humorally mediated disorder.
Wingerchuk DM, Weinshenker BG: Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003, 60:848–853.
Filippini G, Brusaferri F, Sibley WA, et al.: Corticoster-oids or ACTH for acute exacerbations in multiple sclerosis. In Cochrane Library. Oxford; Wiley Inter-Science. 2004, Issue 4.
Beck RW, Cleary PA, Anderson Jr MM, et al.: A random-ized, controlled trial of corticosteroids in the treat-ment of acute optic neuritis. N Engl J Med 1992, 326:581–588.
The Optic Neuritis Study Group: Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997, 115:1545–1552.
Brusaferri F, Candelise L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000, 247:435–442.
Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886. This is the first randomized controlled study of an interven-tion for corticosteroid-refractory exacerbations of demyelinat-ing disease.
Ruprecht K, Klinker E, Dintelmann T, et al.: Plasma exchange for severe optic neuritis: Treatment of 10 pat i ent s. Neurology 2004, 63:1081–1083. This case series suggests that plasma exchange also may bene-fit refractory optic neuritis.
Chrousos GA, Kattah JC, Beck RW, et al.: Side effects of glucocorticoid treatment: experience of the optic neuritis Treatment Trial. JAMA 1993, 269:2110–2112.
Mandler RN, Ahmed W, Dencoff JE: Devic’s neuro-myelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219–1220. This was the first case series to show NMO stability with immunosuppressive therapy.
Remuzzi G, Lesti M, Gotti E, et al.: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503–512.
Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders. Prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484–1492.
Cree B, Lamb S, Chin A, et al.: Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 2004, 62(Suppl 5):A492. This abstract describes initial favorable experience with rituximab.
Bakker J, Metz L: Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265–267.
Hartung HP, Gonsette R, Konig N, et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-con-trolled, double-blind, randomized, multicenter trial. Lancet 2002, 360:2018–2025.
Goodin DS, Arnason BG, Coyle PK, et al.: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:1332–1338.
Weinstock-Guttman B, Feichter J, Lincoff N, Bakshi R: Mitoxantrone (Novantrone) for treatment of relapsing neuromyelitis optica. Ann Neurol 2004, 56(Suppl 8):S58. Additional evaluation of mitoxantrone, now approved for severe MS, may be warranted but is not a B cell-specific therapy.
Minagar A, Sheremata WA: Treatment of Devic’s disease with methotrexate and prednisone. Intl J MS Care (Serial online) 2000, 2(4).
Bergamaschi R, Uggetti C, Tonietti S, et al.: A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 2003, 250:359–361.
Itoyama Y, Saida T, Tashiro K, et al.: Japanese multi-center, randomized, double-blind trial of interferon beta-1b in relapsing-remitting multiple sclerosis: two year results. Ann Neurol 2000, 48:487. The final results of this study are needed to determine the effects of interferon therapy on the Japanese opticospinal form of MS.
Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of demyelination: predictors of response. Neurology 2001, 58:143–146.
Noseworthy JH, O’Brien PC, Weinshenker BG, et al.: IV immunoglobulin does not reverse established weakness in MS. Neurology 2000, 55:1135–1143.
Noseworthy JH, O’Brien PC, Petterson TM, et al.: A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001, 56:1514–1522.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wingerchuk, D.M., Weinshenker, B.G. Neuromyelitis optica. Curr Treat Options Neurol 7, 173–182 (2005). https://doi.org/10.1007/s11940-005-0010-6
Issue Date:
DOI: https://doi.org/10.1007/s11940-005-0010-6